2022
Challenges in the Clinical Recognition of Acute Flaccid Myelitis and its Implications
Hayes LH, Hopkins SE, Liu S, Pardo CA, Garcia-Dominguez MA, Oleszek J, Yea C, Ciftci-Kavaklioglu B, Yeh EA, Dean J, Sadowsky CL, Desai J, Wiegand S, Farias-Moeller R, Nash K, Thakur KT, Vargas WS, Hong-Routson SJ, Yeshokumar A, Zhou MS, Makhani N, Wilson-Murphy M, Bove R, Zhang B, Benson LA. Challenges in the Clinical Recognition of Acute Flaccid Myelitis and its Implications. The Journal Of Pediatrics 2022, 253: 55-62.e4. PMID: 36115622, DOI: 10.1016/j.jpeds.2022.09.012.Peer-Reviewed Original ResearchMeSH KeywordsCentral Nervous System Viral DiseasesChildEnterovirus InfectionsHumansMyelitisNeuromuscular DiseasesRetrospective StudiesConceptsAcute flaccid myelitisInitial diagnosisCase definitionRetrospective multicenter studyPrevention case definitionInitial differential diagnosisNew treatment optionsInitial clinical encounterIntensive care monitoringRespiratory decompensationImmunomodulatory treatmentIntravenous immunoglobulinVentilatory supportPediatric patientsClinical featuresAcute careMulticenter studyTreatment optionsClinical recognitionTreatment paradigmClinical impactDifferential diagnosisPatientsDisease controlClinical encounters
2020
Acute flaccid myelitis: cause, diagnosis, and management
Murphy O, Messacar K, Benson L, Bove R, Carpenter J, Crawford T, Dean J, DeBiasi R, Desai J, Elrick M, Farias-Moeller R, Gombolay G, Greenberg B, Harmelink M, Hong S, Hopkins S, Oleszek J, Otten C, Sadowsky C, Schreiner T, Thakur K, Van Haren K, Carballo C, Chong P, Fall A, Gowda V, Helfferich J, Kira R, Lim M, Lopez E, Wells E, Yeh E, Pardo C, group A, Salazar-Camelo A, Mithal D, Wilson-Murphy M, Bauer A, Watkins C, Abzug M, Dominguez S, Press C, Yang M, Ahsan N, Ramos-Platt L, Tiongson E, Seruya M, Tilton A, Katz E, Kirschen M, Shah A, Ulloa E, Yum S, Mondok L, Blaufuss M, Rosenfeld A, Vargas W, Zucker J, Yeshokumar A, Navis A, Chao K, Hagen K, Melicosta M, Porter C, Tunney M, Scheuermann R, Duggal P, Pekosz A, Bayliss A, Moore M, Belzberg A, Bembea M, O'Brien C, Riggs R, Nance J, Milstone A, Rice J, Garcia-Dominguez M, Flanagan E, Tillema J, Bosques G, Bhatia S, Gordon-Lipkin E, Deike D, Revivo G, Zlotolow D, deFiebre G, Lazerow P, Lotze T, Bitnun A, Davidge K, Vajsar J, Moore A, Konersman C, Nash K, Strober J, Gupta N, Chiu C, Sweeney M, Jackson W, Simon D, Thakkar K, Cheng J, Luce J, Das S, Vogt M, Vu N, Gofshteyn J, Makhani N, Patel P. Acute flaccid myelitis: cause, diagnosis, and management. The Lancet 2020, 397: 334-346. PMID: 33357469, PMCID: PMC7909727, DOI: 10.1016/s0140-6736(20)32723-9.Peer-Reviewed Original ResearchMeSH KeywordsCentral Nervous System Viral DiseasesChildEnterovirus InfectionsGlobal HealthHumansMagnetic Resonance ImagingMuscle HypotoniaMuscle WeaknessMyelitisNeuromuscular DiseasesPatient Outcome AssessmentConceptsAcute flaccid myelitisNon-polio enterovirus infectionMajor public health challengeAcute neurological illnessCerebrospinal fluid characteristicsPolio-like illnessSubstantial residual disabilityProfound muscle weaknessLong-term outcomesTargeted therapeutic approachesPublic health challengeLong-term rehabilitationResidual disabilityAcute phaseClinical featuresClinical presentationEnterovirus infectionImmunological featuresMuscle weaknessNeurological illnessTherapeutic approachesHost-virus interactionsPathogen factorsHealth challengesDiagnosis
2018
Safety, tolerability, and efficacy of fluoxetine as an antiviral for acute flaccid myelitis
Messacar K, Sillau S, Hopkins SE, Otten C, Wilson-Murphy M, Wong B, Santoro JD, Treister A, Bains HK, Torres A, Zabrocki L, Glanternik JR, Hurst AL, Martin JA, Schreiner T, Makhani N, DeBiasi RL, Kruer MC, Tremoulet AH, Van Haren K, Desai J, Benson LA, Gorman MP, Abzug MJ, Tyler KL, Dominguez SR. Safety, tolerability, and efficacy of fluoxetine as an antiviral for acute flaccid myelitis. Neurology 2018, 92: e2118-e2126. PMID: 30413631, PMCID: PMC6512883, DOI: 10.1212/wnl.0000000000006670.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsCentral Nervous System Viral DiseasesChildChild, PreschoolFemaleFluoxetineHumansMaleMyelitisNeuromuscular DiseasesRetrospective StudiesTreatment OutcomeConceptsAcute flaccid myelitisSerious adverse eventsFluoxetine-treated patientsEfficacy of fluoxetineEV-D68Initial examinationPoor long-term outcomesImproved neurologic outcomeMulticenter cohort studyClass IV evidenceAdverse effect ratesDose of fluoxetinePropensity-adjusted analysisLong-term outcomesUnexposed patientsNeurologic outcomeUntreated patientsAdverse eventsCohort studyPrimary outcomeUS patientsStudy criteriaEnterovirus D68PatientsEffect rate